Bluebird

Project Brief

Bluebird is a longevity startup with a cellular age-reversal platform and a $25M raise to fund it. The science was strong, but the central claim, reversing biological age by up to seven years, was bold enough to trigger doubt in a room of investors. The deck had to make that claim believable, earning trust slide by slide before it asked for anything.

Type

Longevity / Biotech

Our Approach

The deck follows a problem-to-ask arc, paced so credibility compounds rather than front-loading the claim. It opens on stakes, not the product. Ageing drives 80% of disease and costs over $5 trillion a year, so the urgency lands before Bluebird is even named. Only once the problem is established does the deck state its claim and back it with a rats → humans → scale proof chain, turning a bold statement into a logical progression. From there it opens up the market, the moat, and the model.

We gave every headline number its own slide, so the 7 years, the $9 trillion, and the $25M each get a clean moment instead of competing for attention.

Final Result

Bluebird’s raw research and claims, shaped into a clear problem-to-ask narrative built to hold a room of investors. The bold seven-year claim now reads as evidence rather than a boast, and every key number lands in its own moment, so the deck carries belief from the opening problem all the way to the $25M ask.

Have a project in mind? Let’s discuss with us!

Let's Talk